R&D Law Grant and Methotrexate-Free Dosing: Protalix's Quiet Quarter of Building Blocks

PLX leverages new tax benefits and a differentiated PRX-115 design to reinforce its small but growing Elfabrio franchise.

PLX · Earnings Call · 2026-08-12

Financial Momentum Amid Small-Cap Volatility

Protalix BioTherapeutics' Q2 2026 earnings call paints a picture of steady execution against a backdrop of a long-term stock decline (the full-series return is -96.7%, with a recent 90-day gain of +3.5%). The company's revenue story centers on Elfabrio sales through Chiesi, which continue to drive growth. As CFO Gilad Mamlok noted, “Total revenues were $19.9 million compared to $15.7 million in the second quarter of 2025.” — Gilad Mamlok, Senior Vice President and Chief Financial Officer · 2026-08-12 This consistent top-line improvement is reinforced by a healthy gross margin (87.8% in the latest filed quarter) and a strong cash position with no debt—management highlighted,

We have no outstanding debt or warrants, providing us with substantial financial flexibility to support our continued pipeline advancements.
Gilad Mamlok, Senior Vice President and Chief Financial Officer · 2026-08-12

PRX-115: Differentiating Uricase in the Gout Market

The most interesting strategic update is in the clinical pipeline, specifically the RELEASE study for PRX-115, a differentiated uricase. Management outlined a trial design that includes arms with and without methotrexate, as well as varying dosing frequencies. CEO Dror Bashan emphasized the potential of a methotrexate-free or less-frequent regimen: “but also a lower frequency of using the drug is also a big advantage, and we potentially can have both.” — Dror Bashan, President and CEO · 2026-08-12 This echoes prior commentary—in March 2026, Dror had said, “I think if indeed we hit, we have a very nice potential asset.” — Dror Bashan, President and CEO · 2026-03-18 The company also referenced the growing gout market, with Krystexxa revenues trending up, suggesting a ripe opportunity for a differentiated entrant.

R&D Law Grant: A Novel Financial Tailwind

A new and company-specific keyword emerged this quarter: R&D law. The prepared remarks attributed a $2.1 million reduction in R&D expense to a grant now available under the new Israeli R&D law. This is a meaningful, repeatable benefit that improves the bottom line while the company funds the RELEASE study. This was complemented by a GILTI-related tax increase, but the net effect was a swing to net income of $3.8 million versus $0.16 million a year ago. The improved profitability is reflected in the fundamentals snapshot: Total Revenue rose to $34M in the latest filed quarter, up 234% year-over-year. The trend is clearly positive, and the company reiterated its full-year guidance, citing continued Elfabrio growth and the recent European approval of the every-4-weeks dosing regimen.

Outlook and Why It Matters

Protalix is not a household name, but it occupies a niche with a commercial product, a partnered sales force, and a pipeline aimed at high-unmet-need indications. The combination of a new tax credit, a clear clinical trial design that could yield a best-in-class profile, and a partner (Chiesi) that is executing well makes this quarter more than just a routine update. As Dror stated in the opening, “Our results today reflect the strength of our profitable commercial partnerships, and we remain confident in our outlook for this year.” — Dror Bashan, President and CEO · 2026-08-12 The market has yet to reward the stock, but the underlying building blocks—revenue growth, an innovative R&D incentive, and a differentiated gout candidate—suggest latent value.